Latanoprost - Laboratoires Thea

Drug Profile

Latanoprost - Laboratoires Thea

Alternative Names: LUDPF; Monopost; Monoprost; Non-preserved latanoprost - Laboratoires Thea

Latest Information Update: 09 May 2015

Price : $50

At a glance

  • Originator Laboratoires Thea
  • Developer Clermont Pharmaceuticals; Laboratoires Thea
  • Class Antiglaucomas; Prostaglandins; Small molecules
  • Mechanism of Action Prostaglandin F2 alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Glaucoma; Ocular hypertension

Most Recent Events

  • 01 Oct 2013 Launched for Ocular hypertension in European Union prior to October 2013 (Ophthalmic)
  • 01 Oct 2013 Launched for Glaucoma in European Union prior to October 2013 (Ophthalmic)
  • 13 Sep 2013 Laboratoires Thea initiates a phase IV trial in Glaucoma or Ocular hypertension in Spain (EudraCT2013-001250-10)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top